Synaptic Therapy Alzheimer's Research Trial (START): A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease Over 18 Months.

This is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's disease.

Start Date28 Jun 2023

Sponsor / Collaborator

Cognition Therapeutics, Inc.

[+1]

NCT05893537 / RecruitingPhase 2

A Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).

This is a Phase 2, prospective, multicenter, randomized, double-masked, placebo-controlled 104-week study to assess the efficacy, safety, and tolerability of orally delivered CT1812 compared to placebo in participants with GA associated with dry AMD.

Start Date16 Jun 2023

Sponsor / Collaborator

Cognition Therapeutics, Inc.

NCT05225415 / Active, not recruitingPhase 2

A Randomized, Double-blind, Placebo-controlled, Phase 2, 6-month Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies

Multi-center, randomized, double-blind, placebo-controlled, 6- month study in subjects with mild to moderate Dementia with Lewy Bodies.

Start Date19 May 2022

Sponsor / Collaborator

Cognition Therapeutics, Inc.

[+1]

100 Clinical Results associated with CT-1812

100 Translational Medicine associated with CT-1812

100 Patents (Medical) associated with CT-1812

Literatures (Medical) associated with CT-1812

01 Oct 2023·Current neurology and neuroscience reports

Lewy Body Dementia: An Overview of Promising Therapeutics

Review

Author: Skylar-Scott, Irina A ; Sha, Sharon J

PURPOSE OF REVIEW:

Lewy body dementia (LBD) encompasses dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD). This article will emphasize potential disease-modifying therapies as well as investigative symptomatic treatments for non-motor symptoms including cognitive impairment and psychosis that can present a tremendous burden to patients with LBD and their caregivers.

RECENT FINDINGS:

We review 11 prospective disease-modifying therapies (DMT) including four with phase 2 data (neflamapimod, nilotinib, bosutinib, and E2027); four with some limited data in symptomatic populations including phase 1, open-label, registry, or cohort data (vodabatinib, ambroxol, clenbuterol, and terazosin); and three with phase 1 data in healthy populations (Anle138b, fosgonimeton, and CT1812). We also appraise four symptomatic therapies for cognitive impairment, but due to safety and efficacy concerns, only NYX-458 remains under active investigation. Of symptomatic therapies for psychosis recently investigated, pimavanserin shows promise in LBD, but studies of nelotanserin have been suspended. Although the discovery of novel symptomatic and disease-modifying therapeutics remains a significant challenge, recently published and upcoming trials signify promising strides toward that aim.

12 May 2023·Translational neurodegeneration

A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer's disease using an indwelling CSF catheter.

Letter

Author: LeVine, Harry ; Yurko, Raymond ; Sheline, Yvette I ; Catalano, Susan M ; LaBarbera, Kelsie M ; Guttendorf, Robert J ; Zetterberg, Henrik ; Yuede, Carla M ; Edwards, Hannah M ; Waybright, Lora ; DeKosky, Steven ; Börjesson-Hanson, Anne ; Caggiano, Anthony O ; Blennow, Kaj ; Izzo, Nicholas J ; Davis, Charles S ; Schneider, Lon S ; Hamby, Mary E ; Grundman, Michael ; Cirrito, John R ; Gardiner, Woodrow D ; Morgan, Roger

01 May 2023·CNS drugs

Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental Disorders.

Review

Author: Tencomnao, Tewin ; Malar, Dicson S ; Thitilertdecha, Premrutai ; Ruckvongacheep, Kanokphorn S ; Brimson, James M ; Brimson, Sirikalaya

The sigma-1 receptor is a 223 amino acid-long protein with a recently identified structure. The sigma-2 receptor is a genetically unrelated protein with a similarly shaped binding pocket and acts to influence cellular activities similar to the sigma-1 receptor. Both proteins are highly expressed in neuronal tissues. As such, they have become targets for treating neurological diseases, including Alzheimer's disease (AD), Huntington's disease (HD), Parkinson's disease (PD), multiple sclerosis (MS), Rett syndrome (RS), developmental and epileptic encephalopathies (DEE), and motor neuron disease/amyotrophic lateral sclerosis (MND/ALS). In recent years, there have been many pre-clinical and clinical studies of sigma receptor (1 and 2) ligands for treating neurological disease. Drugs such as blarcamesine, dextromethorphan and pridopidine, which have sigma-1 receptor activity as part of their pharmacological profile, are effective in treating multiple aspects of several neurological diseases. Furthermore, several sigma-2 receptor ligands are under investigation, including CT1812, rivastigmine and SAS0132. This review aims to provide a current and up-to-date analysis of the current clinical and pre-clinical data of drugs with sigma receptor activities for treating neurological disease.

News (Medical) associated with CT-1812

10 Jun 2024

·www.biospace.com

Amyloid Remains a Key Target in Next-Generation Alzheimer’s Treatments

Pictured: A colorful brain surrounded by pill bottles/Taylor Tieden for BioSpace With 164 clinical trials assessing 127 drugs in the pipeline, momentum in the Alzheimer’s space is on an upward swing—and while the field has expanded from its initial targets of amyloid beta and tau, experts believe they will remain a pivotal part of the treatment landscape. Five or 10 years ago, 75% of the drugs in development for Alzheimer’s were anti-amyloid beta (Aβ) or anti-tau drugs, said Howard Fillit, co-founder and chief science officer of the Alzheimer’s Drug Discovery Foundation. “Today that’s completely reversed, as 75% of the drugs in clinical development are non-amyloid, non-tau drugs,” Fillit told BioSpace. The framework for new approaches coming down the pipeline is to confront the leading risk factor for Alzheimer’s disease: age. The majority of clinical development aims to address age-related issues such as neuroinflammation, epigenetic autophagy, metabolic and mitochondrial disorders, and vascular problems, Fillit noted. Beta-amyloid has long been a prime suspect in Alzheimer’s disease progression. The protein is chemically sticky and accumulates in plaques that are a hallmark trait of the degenerative disease. While the so-called amyloid hypothesis has been “very exciting” for years, “nobody believes . . . that there’s a single target,” said Lisa Ricciardi, CEO of Cognition Therapeutics, which is focused on neurodegenerative and neuro-ophthalmic diseases. Fillit concurred, saying that combination therapy is the future and anti-amyloid therapies will remain an important part of treating patients. Optimizing Administration and Brain Penetration With Biogen and Eisai’s Leqembi on the market and an FDA advisory committee convening today to discuss Eli Lilly’s donanemab—both amyloid-clearing antibody treatments—companies developing anti-amyloid therapeutics are pivoting toward next-generation development. Two key areas targeted for improvement are administration and blood-brain barrier penetration, Fillit said. Both Leqembi and donanemab are administered intravenously, every two weeks for the former and every four weeks for the latter. In addition to infusion center visits, patients on these therapies are looking at a series of imaging requirements to ensure brain health as they’re treated. Long-term data is not yet available for these new antibodies, so length of treatment is still unknown. Aiming to relieve some of the burdens of treatment, both subcutaneous versions and oral therapies targeting beta-amyloid are currently in development. Aliada Therapeutics’ monthly, subcutaneous antibody, ALIA-1758—in-licensed from J&J’s Janssen and moving toward Phase I ascending dose clinical studies—is uniquely engineered for both delivery and plaque clearing. Targeting pyroglutamate amyloid beta, which is similar to the epitope targeted by donanemab, ALIA-1758 utilizes the transferrin receptor to drive its cargo to cells and force degradation and elimination of the plaques, explained John Dunlop, chief scientific officer at Aliada. By transporting the cargo in this way, a higher concentration of the antibodies is delivered across the blood-brain barrier to drive therapeutic benefit, he told BioSpace. While first-generation anti-amyloid therapies show “some” evidence of efficacy, “I think we all agree in the field: there is significant room for improvement,” Dunlop said. Meanwhile, Cognition is tackling amyloid beta with an oral, brain-penetrant small molecule. Instead of focusing on removing plaques from the brain, Cognition’s candidate, CT1812, prevents the binding of toxic oligomers to synapses in a neuroprotective approach that acts earlier in the amyloid cascade to slow cognitive decline and disease progression, Ricciardi explained. An 18-month Phase II trial is underway with 540 early-to-mild Alzheimer’s patients, and Cognition expects results from an earlier Phase II trial mid-summer, she said. With the currently approved anti-amyloid antibodies, “a very tiny amount of the drug actually makes it into the brain,” Ricciardi said, so Cognition’s founding scientists prioritized a high degree of blood-brain barrier (BBB) penetration for its lead asset. Roche is also focused on the BBB dilemma. After a failed attempt at developing an anti-amyloid antibody for Alzheimer’s, the Swiss pharma is now testing an antibody delivered by its Brainshuttle module, which also utilizes the transferrin receptor. Initial data shows trontinemab had “substantially higher CNS exposure due to shuttling” than the first drug, gantenerumab, with dose-dependent amyloid plaque lowering capabilities. Eisai and Biogen are on board with improving administration, too. The partners initiated a rolling Biologics License Application (BLA) last month for a weekly, subcutaneous version of Leqembi. Improving Safety Fillit said about 20% of patients experience an adverse event from the current anti-amyloid antibody treatments, but most are not serious. Only around 2% of patients have a serious adverse event, he noted, so with Alzheimer’s being one of the leading causes of death, the “product pro terms of risk and benefit is favorable.” However, certain populations are not eligible for treatments like Leqembi. Patients with two copies of APOE4, a gene variant that carries a high risk of Alzheimer’s, and those on anticoagulants who are at higher risk for brain swelling and bleeds, leading to warnings in the product’s label. “When you look at the criteria for patients who can actually take the [antibody] and you use all the exclusion criteria, it comes down to a fraction of the population. That was surprising to me,” Ricciardi said. In contrast, Cognition’s trials have been open to all comers with mild-to-moderate Alzheimer’s. So far, Ricciardi said the company has yet to see the amyloid-related imaging abnormalities (ARIA)—a form of brain swelling—that have occurred with Leqembi and donenamab. Since CT1812 works preventatively, it isn’t removing plaques, which can lead to tears in the vessels of the brain or swelling, she explained. Similarly, due to its mechanism, Aliada’s candidate doesn’t engage the microglia and isn’t associated with release of pro-inflammatory cytokines. The company therefore does not anticipate any ARIA incidence as it begins clinical trials, which Dunlop believes should “open up the possibility to really get into a broad population.” And Roche’s Brainshuttle delivery may allow for lower doses of the antibody due to superior BBB penetration. Experts believe this could lower ARIA risk. In its Brainshuttle AD trial, Roche reported a “low incidence of ARIA despite robust amyloid lowering,” with two asymptomatic or mild cases of ARIA in the higher 1.8 mg/kg cohort. Combination Treatments Overall, experts believe amyloid beta will be an important target in a multi-pronged approach to treating the progressive, memory-robbing disease. In the future, “we’re going to have precision medicine for Alzheimer’s disease with combination therapy,” Fillit predicted. In Cognition’s START trial, patients are allowed to come in on background Leqembi. Those who have been on the antibody for three to four months can be included in the trial in order to see how the drugs work together. “As far as I know, that’s the first trial looking at real-time combination therapy,” Ricciardi said. Cognition is hoping to find a “great homeostasis” in the combined effort, with Leqembi clearing out old plaques while CT1812 protects the neurons and clears out oligomers. Amyloid triggers a pathological cascade of immune activation, brain inflammation and changes to the tau protein, Dunlop said. Aliada is thinking carefully about a complementary tau-targeting asset for its pipeline. As more targets emerge for Alzheimer’s disease, one thing is clear to Aliada’s leadership team, Dunlop added: “Amyloid is always going to be around.” Kate Goodwin is a freelance life science writer based in Des Moines, Iowa. She can be reached at kate.goodwin@biospace.com and on LinkedIn.

Phase 1Phase 2

21 May 2024

·www.globenewswire.com

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease

PURCHASE, N.Y., May 21, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, has released its eighth Conversations video podcast episode: “Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease.” This episode reviews how beta amyloid (Aβ) oligomers cause synaptic dysfunction, which is correlated with cognitive decline. This conversation features a discussion of newly published research showing that Aβ oligomers bind to synapses in brain tissue of Alzheimer’s patients and how CT1812 acts to reverse their binding and reduce synaptotoxicity. Additionally, the panelists discuss using quantitative electroencephalography (EEG) as a real-time biomarker of synaptic function. In the Phase 2 ‘SEQUEL’ study of CT1812 in mild-to-moderate Alzheimer’s disease, four weeks of treatment was associated with trends to improvement in synaptic function and brain connectivity. Finally, Dr. Hamby summarized results of proteomic analysis demonstrating the impact of CT1812 treatment on proteins and pathways altered in Alzheimer’s disease, namely, synapse, amyloid beta processing and neuroinflammation. Anthony Caggiano, M.D., Ph.D. CMO and head of R&D for Cognition Therapeutics moderates the discussion joined by VP of research, Mary Hamby, Ph.D. and two leading experts: Everard (Jort) Vijverberg, MD, PhD, Staff Neurologist and CNS Trial Specialist at the Amsterdam Alzheimer Center at Amsterdam NeuroscienceTara Spires Jones, DPhil, Personal Chair of Neurodegeneration and Deputy Director of the University of Edinburgh’s Centre for Discovery Brain Sciences Listen to episode eight, “Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease” on the Conversations tab of the Cognition website. Health Care Disclaimer Our podcast series does not constitute the practice of medical advice, diagnosis or treatment. Always talk to your health care provider for diagnosis and treatment, including your specific medical needs. If you have or suspect that you have a medical problem or condition, please contact a qualified health care professional immediately. About Cognition Therapeutics, Inc.Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). We believe CT1812 and our pipeline of σ-2 receptor modulators can regulate pathways that are impaired in these diseases. We believe that targeting the σ-2 receptor with CT1812 represents a mechanism functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. More about Cognition Therapeutics and its pipeline can be found at https://cogrx.com. Forward Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our product candidates, including CT1812, and any expected or implied benefits or results, including that initial clinical results observed with respect to CT1812 will be replicated in later trials and our clinical development plans, including statements regarding our clinical studies of CT1812 and any analyses of the results therefrom, are forward-looking statements. These statements, including statements relating to the timing and expected results of our clinical trials, involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials being predictive of the results of early or later-stage clinical trials; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that the we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; impacts of ongoing global and regional conflicts; the impact of the COVID-19 pandemic on our business, supply chain and labor force; and the risks and uncertainties described more fully in the “Risk Factors” section of our annual and quarterly reports filed with the Securities & Exchange Commission and are available at www.sec.gov. These risks are not exhaustive and we face both known and unknown risks. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contact Information: Cognition Therapeutics, Inc. info@cogrx.com Casey McDonald (media) Tiberend Strategic Advisors, Inc. cmcdonald@tiberend.com Mike Moyer (investors)LifeSci Advisorsmmoyer@lifesciadvisors.com

Phase 2Clinical Result

07 May 2024

·www.globenewswire.com

Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update

- Topline Results from SHINE Study in Mild-to-Moderate Alzheimer’s Expected Mid-2024 -- SHIMMER Study in Dementia with Lewy Bodies Completed Enrollment of 130 Participants - PURCHASE, N.Y., May 07, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), today reported financial results for the first quarter ended March 31, 2024, and provided a business update. “During the first few months of 2024, we completed enrollment of 130 adults with mild-to-moderate dementia with Lewy bodies (DLB) in the Phase 2 SHIMMER study, exceeding our target. In addition, we are preparing for the analysis of topline results from the Phase 2 SHINE study in mild-to-moderate Alzheimer’s disease,” said Lisa Ricciardi, Cognition’s president and CEO. “We will report topline SHINE results in a press release once they become available and plan to make further presentations during the 2024 Alzheimer’s Association International Conference.” Business and Corporate Highlights Completed enrollment of 130 adults with mild-to-moderate DLB in the Phase 2 SHIMMER study, with an expectation that topline results will be reported after the last participants have completed six months of treatmentCompleted follow-on public offering of common stock receiving net proceeds of $11.9 million including the over-allotmentPublished manuscript with collaborators in Acta Neuropathologica describing proximity of sigma-2 (σ-2) receptor to cellular prion protein and Aβ oligomers on Alzheimer's brain synapsesPresented proteomics analyses from SPARC and SEQUEL participants at the AD/PD™ 2024 Alzheimer's & Parkinson's Diseases ConferenceContinued progress in Phase 2 START study of CT1812 in early Alzheimer’s disease and Phase 2 MAGNIFY study in geographic atrophy secondary to dry age-related macular degeneration First Quarter 2024 Financial Results Cash and cash equivalents as of March 31, 2024 were approximately $34.7 million and total grant funds remaining from the NIA were $62.3 million. Cash and cash equivalents includes net proceeds of approximately $11.9 million from the March 2024 underwritten follow-on public offering of 7,557,142 shares of common stock. The Company estimates that it has sufficient cash to fund operations and capital expenditures through the second quarter of 2025. Research and development expenses were $10.6 million for the quarter ended March 31, 2024, compared to $5.4 million for the comparable period in 2023. The increase was primarily related to higher costs associated with advancing our clinical programs, including Phase 2 trial activities with contract research organizations, personnel, and manufacturing cost. General and administrative expenses were $3.5 million for the quarter ended March 31, 2024, compared to $3.5 million for the comparable period in 2023. The fluctuation of general and administrative expenses was insignificant period over period. The Company reported a net loss of $9.2 million, or $(0.27) per basic and diluted share for the first quarter ended March 31, 2024, compared to a net loss of $6.2 million, or $(0.21) per basic and diluted share for the same period in 2023. About Cognition Therapeutics:Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). We believe CT1812 and our pipeline of σ-2 receptor modulators can regulate pathways that are impaired in these diseases. We believe that targeting the σ-2 receptor with CT1812 represents a mechanism functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. More about Cognition Therapeutics and its pipeline can be found at https://cogrx.com/. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, are forward-looking statements. These statements, including statements relating to the timing and expected results of our clinical trials, upcoming presentations on our clinical trials, and cash runway, involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data and pre-clinical studies being predictive of the results of clinical trials; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that the we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; the impacts of ongoing global and regional conflicts; the impact of the COVID-19 pandemic on our business, supply chain and labor force; and the risks and uncertainties described in the “Risk Factors” section of our annual and quarterly reports filed the Securities Exchange Commission. These risks are not exhaustive and we face both known and unknown risks. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Cognition Therapeutics, Inc.Unaudited Selected Financial Data (in thousands, except share and per share data amounts) Three Months Ended March 31,Consolidated Statements of Operations Data: 2024 2023Operating Expenses: Research and development $10,553 $5,430 General and administrative 3,549 3,543 Total operating expenses 14,102 8,973 Loss from operations (14,102) (8,973)Other income (expense): Grant income 4,912 3,426 Other income (expense), net 244 (615)Interest expense (10) (10)Loss on currency translation from liquidation of subsidiary (195) — Total other income, net 4,951 2,801 Net loss $(9,151) $(6,172)Foreign currency translation adjustment, including reclassifications 195 4 Total comprehensive loss $(8,956) $(6,168)Net loss per share: Basic $(0.27) $(0.21)Diluted $(0.27) $(0.21)Weighted-average common shares outstanding: Basic 33,735,269 29,094,592 Diluted 33,735,269 29,094,592 As of(in thousands) March 31,2024 December 31,2023Consolidated Balance Sheet Data: Cash and cash equivalents $34,671 $29,922 Total assets 38,851 35,163 Total liabilities 9,991 10,689 Accumulated deficit (150,340) (141,189)Total stockholders’ equity 28,860 24,474 Contact Information:Cognition Therapeutics, Inc.info@cogrx.comCasey McDonald (media)Tiberend Strategic Advisors, Inc.cmcdonald@tiberend.comMike Moyer (investors)LifeSci Advisorsmmoyer@lifesciadvisors.com

Financial StatementPhase 2

100 Deals associated with CT-1812

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
dry age-related macular degeneration	Phase 2	US	Cognition Therapeutics, Inc.	16 Jun 2023
Geographic Atrophy	Phase 2	US	Cognition Therapeutics, Inc.	16 Jun 2023
Lewy Body Disease	Phase 2	US	Cognition Therapeutics, Inc.	19 May 2022
Alzheimer Disease	Phase 2	US	National Institute on Aging	10 Oct 2018
Alzheimer Disease	Phase 2	US	Cognition Therapeutics, Inc.	10 Oct 2018
Alzheimer Disease	Phase 2	AU	Cognition Therapeutics, Inc.	10 Oct 2018
Alzheimer Disease	Phase 2	AU	National Institute on Aging	10 Oct 2018
Alzheimer Disease	Phase 2	CZ	National Institute on Aging	10 Oct 2018
Alzheimer Disease	Phase 2	CZ	Cognition Therapeutics, Inc.	10 Oct 2018
Alzheimer Disease	Phase 2	NL	Cognition Therapeutics, Inc.	10 Oct 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05225389 (CTgov)	Phase 1	Alzheimer Disease	8	CT1812+[14C]-CT1812	fenzvlviqi(qortxbjrxp) = vkhrjwirap rfcpyumtgk (tusvcloijw, myqqwycxsk - ufxkeshiyv) View more	-	21 Jul 2023
NCT03493282 (SPARC, Corporate Publications) Manual	Phase 1/2	Alzheimer Disease	23	CT 1812	nnctoujlns(encmnsotuy) = SAE has not been reported. tjepxkhejd (kklihlrcqp ) View more	Positive	04 Aug 2022
NCT03493282 (SPARC, Corporate Publications) Manual	Phase 1/2	Alzheimer Disease	23	Placebo		Positive	04 Aug 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis